Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib mainte-nance therapy and comparison to the general population.

Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rumpold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N.

Leuk Lymphoma. 2020 Feb;61(2):377-386. doi: 10.1080/10428194.2019.1666381. Epub 2019 Sep 26.